List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3276476/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evidence that fibroblasts derive from epithelium during tissue fibrosis. Journal of Clinical Investigation, 2002, 110, 341-350.	8.2	1,447
2	Evidence that fibroblasts derive from epithelium during tissue fibrosis. Journal of Clinical Investigation, 2002, 110, 341-350.	8.2	1,098
3	Noninvasive Evaluation of Kidney Hypoxia and Fibrosis Using Magnetic Resonance Imaging. Journal of the American Society of Nephrology: JASN, 2011, 22, 1429-1434.	6.1	298
4	Connective Tissue Growth Factor Expressed in Tubular Epithelium Plays a Pivotal Role in Renal Fibrogenesis. Journal of the American Society of Nephrology: JASN, 2005, 16, 133-143.	6.1	170
5	Progressive renal fibrosis in murine polycystic kidney disease: An immunohistochemical observation. Kidney International, 2000, 58, 587-597.	5.2	143
6	Hepatocyte growth factor counteracts transforming growth factor‵21, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice. FASEB Journal, 2003, 17, 268-270.	0.5	128
7	Conditional Abatement of Tissue Fibrosis Using Nucleoside Analogs to Selectively Corrupt DNA Replication in Transgenic Fibroblasts. Molecular Therapy, 2001, 3, 149-159.	8.2	99
8	The contribution of epithelial-mesenchymal transition to renal fibrosis differs among kidney disease models. Kidney International, 2015, 87, 233-238.	5.2	84
9	Dopamine D1-Like Receptor Antagonist Attenuates Th17-Mediated Immune Response and Ovalbumin Antigen-Induced Neutrophilic Airway Inflammation. Journal of Immunology, 2011, 186, 5975-5982.	0.8	74
10	Recommendations by the Asian Pacific society of nephrology ( <scp>APSN</scp> ) on the appropriate use of <scp>HIFâ€₽H</scp> inhibitors. Nephrology, 2021, 26, 105-118.	1.6	60
11	Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS ONE, 2020, 15, e0236132.	2.5	46
12	Fibroblast Expression of an IκB Dominant-Negative Transgene Attenuates Renal Fibrosis. Journal of the American Society of Nephrology: JASN, 2010, 21, 2047-2052.	6.1	44
13	Possible Mechanisms of Renal Fibrosis. Contributions To Nephrology, 1996, 118, 147-154.	1.1	42
14	Dexamethasone Induces Connective Tissue Growth Factor Expression in Renal Tubular Epithelial Cells in a Mouse Strain-Specific Manner. American Journal of Pathology, 2006, 168, 737-747.	3.8	42
15	Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database. Diabetes Care, 2021, 44, 2542-2551.	8.6	42
16	A Possible Anti-Inflammatory Role of Angiotensin II Type 2 Receptor in Immune-Mediated Glomerulonephritis during Type 1 Receptor Blockade. American Journal of Pathology, 2006, 169, 1577-1589.	3.8	41
17	Clinical guides for atypical hemolytic uremic syndrome in Japan. Clinical and Experimental Nephrology, 2016, 20, 536-543.	1.6	41
18	The Japanese clinical practice guideline for acute kidney injury 2016. Clinical and Experimental Nephrology, 2018, 22, 985-1045.	1.6	40

#	Article	IF	CITATIONS
19	Reduced oxygenation but not fibrosis defined by functional magnetic resonance imaging predicts the long-term progression of chronic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, 964-970.	0.7	40
20	Selective depletion of fibroblasts preserves morphology and the functional integrity of peritoneum in transgenic mice with peritoneal fibrosing syndrome. Kidney International, 2003, 64, 1722-1732.	5.2	38
21	J-CKD-DB: a nationwide multicentre electronic health record-based chronic kidney disease database in Japan. Scientific Reports, 2020, 10, 7351.	3.3	37
22	New Animal Models for Encapsulating Peritoneal Sclerosis—Role of Acidic Solution. Peritoneal Dialysis International, 2001, 21, 349-353.	2.3	36
23	The Japanese Clinical Practice Guideline for acute kidney injury 2016. Journal of Intensive Care, 2018, 6, 48.	2.9	35
24	Inhibition of monocyte chemoattractant protein-1 expression in tubular epithelium attenuates tubulointerstitial alteration in rat Goodpasture syndrome. Kidney International, 2000, 57, 927-936.	5.2	34
25	Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS). Clinical and Experimental Nephrology, 2020, 24, 526-540.	1.6	33
26	Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clinical and Experimental Nephrology, 2019, 23, 112-121.	1.6	31
27	Effects of Vasopressin V1 and V2 Receptor Antagonists on Progressive Renal Failure in Rats. Clinical Science, 1994, 86, 399-404.	4.3	29
28	Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the <scp>J</scp> oint <scp>C</scp> ommittee of the <scp>J</scp> apanese <scp>S</scp> ociety of <scp>N</scp> ephrology and the <scp>J</scp> apan <scp>P</scp> ediatric <scp>S</scp> ociety. Pediatrics International, 2014, 56, 1-5.	0.5	29
29	Poly(ADP-Ribose) Polymerase-1 Enhances Transcription of the Profibrotic CCN2 Gene. Journal of the American Society of Nephrology: JASN, 2008, 19, 933-942.	6.1	27
30	Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the joint committee of the Japanese society of nephrology and the Japan pediatric society. Clinical and Experimental Nephrology, 2014, 18, 4-9.	1.6	24
31	Guidelines for clinical evaluation of chronic kidney disease. Clinical and Experimental Nephrology, 2018, 22, 1446-1475.	1.6	23
32	Biophysical Signals Underlying Myogenic Responses in Rat Interlobular Artery. Hypertension, 1998, 32, 1060-1065.	2.7	22
33	D1-Like Receptor Antagonist Inhibits IL-17 Expression and Attenuates Crescent Formation in Nephrotoxic Serum Nephritis. American Journal of Nephrology, 2009, 30, 274-279.	3.1	22
34	Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. Clinical and Experimental Nephrology, 2018, 22, 1266-1280.	1.6	21
35	A digest of the Evidence-Based Clinical Practice Guideline for Nephrotic Syndrome 2020. Clinical and Experimental Nephrology, 2021, 25, 1277-1285.	1.6	21
36	Angiotensin II type 1 receptor blockade attenuates renal fibrogenesis in an immune-mediated nephritic kidney through counter-activation of angiotensin II type 2 receptor. Biochemical and Biophysical Research Communications, 2004, 314, 403-408.	2.1	20

#	Article	IF	CITATIONS
37	Clinico-pathological features of kidney disease in diabetic cases. Clinical and Experimental Nephrology, 2018, 22, 1046-1051.	1.6	20
38	Efficacy of aerobic exercise on the cardiometabolic and renal outcomes in patients with chronic kidney disease: a systematic review of randomized controlled trials. Journal of Nephrology, 2021, 34, 155-164.	2.0	20
39	Clinical guides for atypical hemolytic uremic syndrome in Japan. Pediatrics International, 2016, 58, 549-555.	0.5	19
40	TGF-β1 and HGF coordinately facilitate collagen turnover in subepithelial mesenchyme. Biochemical and Biophysical Research Communications, 2002, 297, 255-260.	2.1	18
41	Kidney biopsy guidebook 2020 in Japan. Clinical and Experimental Nephrology, 2021, 25, 325-364.	1.6	18
42	ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE. Nephrology, 2020, 25, 12-45.	1.6	17
43	Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS ONE, 2020, 15, e0240402.	2.5	17
44	Transition of adolescent and young adult patients with childhood-onset chronic kidney disease from pediatric to adult renal services: a nationwide survey in Japan. Clinical and Experimental Nephrology, 2016, 20, 918-925.	1.6	16
45	Comparative Study of Efficacy of Plasma Exchange Versus Intravenous Gammaglobulin Treatment on Acute Postinfectious Polyradiculoneuropathy: A Preliminary Report. Therapeutic Apheresis and Dialysis, 1998, 2, 288-291.	0.6	15
46	Safety and effectiveness of eculizumab for adult patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clinical and Experimental Nephrology, 2019, 23, 65-75.	1.6	15
47	Decline of Renal Function Is Associated with Proteinuria and Systolic Blood Pressure in the Morning in Diabetic Nephropathy. Clinical and Experimental Hypertension, 2005, 27, 129-138.	1.3	14
48	A case report suggesting the occurrence of epithelial–mesenchymal transition in obstructive nephropathy. Clinical and Experimental Nephrology, 2009, 13, 385-388.	1.6	14
49	A nationwide survey on clinical practice patterns and bleeding complications of percutaneous native kidney biopsy in Japan. Clinical and Experimental Nephrology, 2020, 24, 389-401.	1.6	13
50	A consensus statement on health-care transition of patients with childhood-onset chronic kidney diseases: providing adequate medical care in adolescence and young adulthood. Clinical and Experimental Nephrology, 2018, 22, 743-751.	1.6	12
51	Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease – An Executive Summary. Nephrology, 2020, 25, 809-817.	1.6	12
52	Controversies of the classification of TMA and the terminology of aHUS. Clinical and Experimental Nephrology, 2018, 22, 979-980.	1.6	10
53	Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney diseases. CKJ: Clinical Kidney Journal, 2009, 2, 192-193.	2.9	9
54	ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE – EXECUTIVE SUMMARY. Nephrology, 2020, 25, 3-11.	1.6	9

#	Article	IF	CITATIONS
55	A digest from evidence-based Clinical Practice Guideline for Polycystic Kidney Disease 2020. Clinical and Experimental Nephrology, 2021, 25, 1292-1302.	1.6	8
56	A digest from evidence-based clinical practice guideline for IgA nephropathy 2020. Clinical and Experimental Nephrology, 2021, 25, 1269-1276.	1.6	8
57	A nationwide prospective cohort study of patients with advanced chronic kidney disease in Japan: The Reach-J CKD cohort study. Clinical and Experimental Nephrology, 2018, 22, 309-317.	1.6	8
58	Nifedipine and Arotinolol in Combination for Accelerated-Malignant Hypertension: Results of One Year Follow-Up Hypertension Research, 1999, 22, 75-80.	2.7	8
59	Targeted expression of a pan-caspase inhibitor in tubular epithelium attenuates interstitial inflammation and fibrogenesis in nephritic but not nephrotic mice. Kidney International, 2012, 82, 980-989.	5.2	7
60	Variations in actual practice patterns and their deviations from the clinical practice guidelines for nephrotic syndrome in Japan: certified nephrologists' questionnaire survey. Clinical and Experimental Nephrology, 2019, 23, 1288-1297.	1.6	7
61	Does Combined Therapy of Ca-channel Blocker and Angiotensin Converting Enzyme Inhibitor Exceed Monotherapy in Renal Protection Against Hypertensive Injury in Rats?. Clinical and Experimental Hypertension, 1996, 18, 243-256.	1.3	6
62	Essentials from clinical practice guidelines for CKD stage G3b-5 2017. Clinical and Experimental Nephrology, 2018, 22, 245-248.	1.6	6
63	Cellular communication network factor 2 (CCN2) promotes the progression of acute kidney injury to chronic kidney disease. Biochemical and Biophysical Research Communications, 2019, 517, 96-102.	2.1	6
64	Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS). Clinical and Experimental Nephrology, 2020, 24, 893-909.	1.6	6
65	Comparison of multiparametric magnetic resonance imaging sequences with laboratory parameters for prognosticating renal function in chronic kidney disease. Scientific Reports, 2021, 11, 22129.	3.3	6
66	Role of Pulse Wave Velocity in Patients with Chronic Kidney Disease Stages 3-5 on Long-Term Follow-Up. Pulse, 2014, 2, 1-10.	1.9	5
67	Successful Prednisolone Therapy in Elderly Patients with Severe Forms of Henoch–Schönlein Purpura Nephritis. Japanese Clinical Medicine, 2015, 6, JCM.S23093.	1.9	5
68	Patients with biopsy-proven nephrosclerosis and moderately impaired renal function have a higher risk for cardiovascular disease: 15 years' experience in a single, kidney disease center. Therapeutic Advances in Cardiovascular Disease, 2015, 9, 77-86.	2.1	5
69	Predictors of long-term prognosis in acute kidney injury survivors who require continuous renal replacement therapy after cardiovascular surgery. PLoS ONE, 2019, 14, e0211429.	2.5	5
70	Comparison of annual eGFR decline among primary kidney diseases in patients with CKD G3b-5: results from a REACH-J CKD cohort study. Clinical and Experimental Nephrology, 2021, 25, 902-910.	1.6	5
71	Application of Magnetic Resonance Imaging in the Evaluation of Nutritional Status: A Literature Review with Focus on Dialysis Patients. Nutrients, 2021, 13, 2037.	4.1	5
72	Improved Outcome Prediction for Patients with Multiple Organ Failure Undergoing Continuous Hemodiafiltration. Therapeutic Apheresis and Dialysis, 2001, 5, 31-35.	0.9	4

#	Article	IF	CITATIONS
73	Combination of Echocardiography and Pulse Wave Velocity Provides Clues for the Differentiation between White Coat Hypertension and Hypertension in Postmenopausal Women. Pulse, 2013, 1, 131-138.	1.9	4
74	Incidence and factors associated with prescribing reninâ€angiotensinâ€system inhibitors in adult idiopathic nephrotic syndrome: A nationwide cohort study. Journal of Clinical Hypertension, 2021, 23, 999-1007.	2.0	4
75	Effects of cell-type-specific expression of a pan-caspase inhibitor on renal fibrogenesis. Clinical and Experimental Nephrology, 2015, 19, 350-358.	1.6	3
76	Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study. Journal of Nephrology, 2022, 35, 1135-1144.	2.0	3
77	Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan. Clinical and Experimental Nephrology, 2022, 26, 974-981.	1.6	3
78	Predictors of early remission of proteinuria in adult patients with minimal change disease: a retrospective cohort study. Scientific Reports, 2022, 12, .	3.3	3
79	Viruses may trigger allopurinol hypersensitivity syndrome. CKJ: Clinical Kidney Journal, 2008, 1, 273-274.	2.9	2
80	Successful Treatment of C1q Nephropathy by Lowâ€Density Lipoprotein Apheresis. Therapeutic Apheresis and Dialysis, 2016, 20, 530-531.	0.9	2
81	Regional prescription surveillance of phosphate binders in the western Saitama area: the substantial role of ferric citrate hydrate in improving serum phosphorus levels and erythropoiesis. Clinical and Experimental Nephrology, 2019, 23, 841-851.	1.6	2
82	Tocilizumab-induced immunocomplex glomerulonephritis: a report of two cases. CEN Case Reports, 2020, 9, 318-325.	0.9	2
83	A digest of the evidence-based Clinical Practice Guideline for Rapidly Progressive Glomerulonephritis 2020. Clinical and Experimental Nephrology, 2021, 25, 1286-1291.	1.6	2
84	INFLUENCE OF THE TIMING OF INITIATING ANTIHYPERTENSIVE THERAPY IN HYPERTENSIVE RATS WITH RENAL FAILURE. Clinical and Experimental Hypertension, 2000, 22, 521-529.	1.3	1
85	Kidney Diseases and Fibrogenesis. The Journal of the Japanese Society of Internal Medicine, 2015, 104, 1658-1664.	0.0	1
86	Framework for estimating renal function using magnetic resonance imaging. Journal of Medical Imaging, 2022, 9, 024501.	1.5	1
87	The relationship between imaging features of diffusion-weighted imaging and prognosis of chronic kidney disease. Kidney International, 2022, 101, 1083.	5.2	1
88	Decline of Renal Function and Progression of Left Ventricular Hypertrophy Are Independently Determined in Chronic Kidney Disease Stages 3-5. Pulse, 2015, 2, 29-37.	1.9	0
89	Glomerular solidification is associated with nephritis-related clinical parameters in IgA nephropathy. Renal Failure, 2019, 41, 893-898.	2.1	0
90	P0822ESTIMATED GFR DECLINE OF PKD PATIENTS IN CKD G3B-5 WAS AS FAST AS THAT OF DKD PATIENTS: A RESULT FROM A JAPANESE COHORT STUDY FOR PATIENTS WITH ADVANCED CKD, THE REACH-J STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0

HIROKAZU OKADA

#	Article	IF	CITATIONS
91	Physical functioning in patients with chronic kidney disease stage G3bâ€5 in Japan: The reachâ€J CKD cohort study. Nephrology, 2021, 26, 981-987.	1.6	0
92	Decreased klotho expression in early aldosteroneâ€induced hypertension. FASEB Journal, 2010, 24, lb698.	0.5	0
93	Gastric and colonic ulcers induced by a nonsteroidal anti-inflammatory drug. Progress of Digestive Endoscopy, 2013, 83, 116-117.	0.0	0
94	A case of constrictive ischemic colitis in the right side of the transverse colon. Progress of Digestive Endoscopy, 2013, 82, 190-191.	0.0	0
95	The Effects of Chronic, and Selective Vasopressin Receptor Blockade in Spontaneously Hypertensive Rats. International Heart Journal, 1995, 36, 538-538.	0.6	0
96	Title is missing!. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 70-74.	0.0	0
97	I. Definition of Diabetic Kidney Disease and Criteria for Consultation with a Nephrology Specialist. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 901-906.	0.0	0
98	2. Strategic Application of Clinical Practice Guideline for CKD Management. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 1698-1707.	0.0	0
99	COVID-19 and the kidney diseases (Adult). Japanese Journal of Pediatric Nephrology, 2022, 35, .	0.0	0
100	MO316: Eculizumab for Adult Patients With Atypical Haemolytic-Uremic Syndrome: Full Dataset Analysis of Post-Marketing Surveillance in Japan. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0